2021 Scientific Sessions

Abstract Session F: Pharmacotherapy in CAD

One month versus Six to Twelve months of Dual antiplatelet therapy after Percutaneous Coronary Intervention with Drug eluting stent: A Meta-Analysis of Randomized control trials
Raahat Bansal, MD1, Rosa Natalia Cruz Torres, MD2, Abhishek Thandra, MD1, Shiva Ponamgi, MBBS1, Himanshu Agarwal, MD3 and Venkata M Alla, MD4, (1)CHI Health Creighton University Medical Center, Omaha, NE, (2)CHI Health Creighton University Medical Center - Bergan Mercy, omaha, NE, (3)-, Omaha, NE, (4)Creighton University, Omaha, NE
1-month dual antiplatelet therapy after Percutaneous Coronary Intervention with Drug eluting stent in High bleeding risk patients: A Pooled analysis
Abhishek Thandra, MD1, Raahat Bansal, MD2, Rosa Natalia Cruz Torres, MD3, Akshay M Balakrishna1, Navya Reddy Alugubelli, MD1, Aiza Ahmad1, Shiva Ponamgi, MBBS1 and Venkata M Alla, MD4, (1)CHI Health Creighton University Medical Center, Omaha, NE, (2)Creighton University School of Medicine, Omaha, NE, (3)CHI Health Creighton University Medical Center - Bergan Mercy, omaha, NE, (4)Creighton University, Omaha, NE
Efficacy and Safety Related to Long-Term Use of Pulmonary Arterial Hypertension Specific Therapies: A Meta-Analysis of Randomized Controlled Trials
Hammad Ur Rahman, MD, SUNY Upstate Medical University, Sayre, NY, Tehseen Hammad, Services Hospital, Lahore, Pakistan and Edo Kaluski, M.D., FSCAI, Guthrie Robert Packer Hospital, Sayre, PA
Long-Term Ischemic and Bleeding Risk with Extended Dual Antiplatelet Therapy After PCI in Patients with 2018 ESC/EACTS Myocardial Revascularization guideline-endorsed High Ishchemic Risk Features
Dr. Haoyu Wang1, Bo Xu2 and Kefei Dou2, (1)Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, (2)Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
See more of: Coronary